# GLP-1 Drugs May Accelerate Muscle Loss in Older Adults
Glucagon-like peptide-1 (GLP-1) drugs like semaglutide and tirzepatide help people lose weight by reducing appetite, but emerging research raises concerns about their effects on older adults. A new analysis suggests these medications accelerate muscle loss in people over 65, potentially increasing frailty risk.
The concern centers on how GLP-1 drugs work. They slow gastric emptying and suppress hunger signals, which leads to rapid weight loss. The problem: that weight loss often includes muscle tissue, not just fat. For older adults, losing muscle mass compounds existing age-related muscle decline, a condition called sarcopenia.
Sarcopenia affects roughly 10 percent of adults over 65 and increases the risk of falls, fractures, disability, and loss of independence. When GLP-1 drugs accelerate this process, the health consequences extend beyond the scale.
Research from gerontologists and geriatricians highlights this disconnect. While younger people using GLP-1 drugs typically lose fat alongside muscle, older adults appear particularly vulnerable to disproportionate muscle loss. This happens because aging already slows muscle protein synthesis, the body's ability to build and maintain muscle tissue.
The solution is not to avoid these drugs entirely. For older adults with type 2 diabetes or obesity-related conditions, GLP-1 medications offer real benefits. Instead, medical teams should combine GLP-1 therapy with resistance training and adequate protein intake. A diet containing 1.2 to 2.0 grams of protein per kilogram of body weight supports muscle preservation during weight loss.
Practitioners now recommend baseline muscle assessments before starting GLP-1 therapy in older patients. Regular strength training, two to three days weekly, helps offset